- Home
- CLDI vs KZIA Comparison
CLDI vs KZIA Comparison
Compare CLDI & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLDI
- KZIA
- Stock Information
- Founded
- CLDI 2014
- KZIA 1994
- Country
- CLDI United States
- KZIA Australia
- Employees
- CLDI N/A
- KZIA N/A
- Industry
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- CLDI Health Care
- KZIA Health Care
- Exchange
- CLDI Nasdaq
- KZIA Nasdaq
- Market Cap
- CLDI 8.7M
- KZIA 9.0M
- IPO Year
- CLDI N/A
- KZIA 1999
- Fundamental
- Price
- CLDI $1.58
- KZIA $7.04
- Analyst Decision
- CLDI
- KZIA Strong Buy
- Analyst Count
- CLDI 0
- KZIA 3
- Target Price
- CLDI N/A
- KZIA $16.00
- AVG Volume (30 Days)
- CLDI 161.6K
- KZIA 187.7K
- Earning Date
- CLDI 11-11-2025
- KZIA 11-14-2025
- Dividend Yield
- CLDI N/A
- KZIA N/A
- EPS Growth
- CLDI N/A
- KZIA N/A
- EPS
- CLDI N/A
- KZIA N/A
- Revenue
- CLDI N/A
- KZIA $1,549,158.00
- Revenue This Year
- CLDI N/A
- KZIA N/A
- Revenue Next Year
- CLDI N/A
- KZIA $49.25
- P/E Ratio
- CLDI N/A
- KZIA N/A
- Revenue Growth
- CLDI N/A
- KZIA 248983.08
- 52 Week Low
- CLDI $1.41
- KZIA $2.86
- 52 Week High
- CLDI $46.68
- KZIA $39.05
- Technical
- Relative Strength Index (RSI)
- CLDI 44.14
- KZIA 44.03
- Support Level
- CLDI $1.51
- KZIA $6.79
- Resistance Level
- CLDI $1.74
- KZIA $7.29
- Average True Range (ATR)
- CLDI 0.10
- KZIA 0.45
- MACD
- CLDI 0.04
- KZIA 0.03
- Stochastic Oscillator
- CLDI 30.43
- KZIA 42.78
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.